Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
OSE ImmunotherapeuticsORPOF 51 EV-to-EBIT is -2.52 as of Jul. 20, 2026. GuruFocus rates ORPOF with a GF Score™ of 51/100 and a GF Value™ of $3.31 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 372 Biotechnology companies, OSE Immunotherapeutics ranks worse than 268816.94% on this metric.
OSE Immunotherapeutics (OTCPK:ORPOF) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
OSE Immunotherapeutics's Enterprise Value for the quarter that ended in Dec. 2025 was $275.01 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. OSE Immunotherapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was $-40.27 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, OSE Immunotherapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
OSE Immunotherapeutics EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, OSE Immunotherapeutics's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where OSE Immunotherapeutics's EV-to-EBIT falls into.
OSE Immunotherapeutics's current Enterprise Value is $101.34 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. OSE Immunotherapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was $-40.27 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSE Immunotherapeutics (ORPOF) has a EV-to-EBIT of -2.52 as of Jul. 20, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on OSE Immunotherapeutics and its competitors. According to the industry distribution chart, OSE Immunotherapeutics ranks #999999 out of 372 companies in the Biotechnology industry.
Is OSE Immunotherapeutics' EV-to-EBIT too high?
OSE Immunotherapeutics' current EV-to-EBIT is -2.52. Based on the distribution chart, OSE Immunotherapeutics ranks #999999 out of 372 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, OSE Immunotherapeutics has a GF Score™ of 51/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does OSE Immunotherapeutics' EV-to-EBIT compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, OSE Immunotherapeutics ranks #999999 out of 372 companies for EV-to-EBIT. This places OSE Immunotherapeutics in the lower half of its industry. The industry median EV-to-EBIT is 13.32. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 13.32, based on 372 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on OSE Immunotherapeutics and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 13.32 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. OSE Immunotherapeutics's current EV-to-EBIT is -2.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OSE Immunotherapeutics stock overvalued right now?
Based on GuruFocus' analysis, OSE Immunotherapeutics (ORPOF) is currently considered Significantly Overvalued. The stock's GF Value™ is $3.31, compared to a current price of $4.43 — trading 33.8% above its estimated fair value. The current EV-to-EBIT is -2.52. OSE Immunotherapeutics' overall GF Score™ is 51/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For OSE Immunotherapeutics (ORPOF), the current EV-to-EBIT is -2.52 as of Jul. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is OSE Immunotherapeutics (ORPOF) Overvalued in 2026?
Based on GuruFocus' analysis, OSE Immunotherapeutics stock appears to be overvalued.
The current stock price of $4.43 is trading 33.8% above its estimated GF Value™ of $3.31.
GuruFocus considers OSE Immunotherapeutics to be Significantly Overvalued.
Key valuation signals for ORPOF:
EV-to-EBIT: -2.52
GF Value™: $3.31 vs. price of $4.43 (33.8% above fair value)
No single metric tells the full story. See the ORPOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
OSE Immunotherapeutics SA is a France-based biotechnology company focused on the development of immunotherapies for immune activation and regulation in the fields of immuno-oncology and autoimmune diseases. The product portfolio of the company comprises Tedopi, OSE-172, OSE-703, FR104 and OSE-127.
51GF Score
Get the complete analysis for ORPOF
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ORPOF has been successfully added to your 
